MétaCan
Menu
← Back to cohort

Efficacy and safety of single agent (SA) or combination (CO) adjuvant chemotherapy (AC) in elderly patients with colon cancer: A Canadian Cancer Institute experience.

2013· article· en· W2589189560 on OpenAlexaffabout
Christina Kim, Jennifer L. Spratlin, Sunita Ghosh, Dawn Elizabeth Armstrong, Karen Mulder

Bibliographic record

VenueJournal of Clinical Oncology · 2013
Typearticle
Languageen
FieldMedicine
TopicCancer Treatment and Pharmacology
Canadian institutionsUniversity of Alberta
Fundersnot available
KeywordsMedicineDiscontinuationCancerInternal medicineColorectal cancerToxicitySurgery

Abstract

fetched live from OpenAlex

e14715 Background: AC for colon cancer is recommended in the fit elderly. The pattern of AC use in elderly patients (pts), the toxicity profile, and survival benefit is unclear. We sought to: 1) determine whether patients ≥65 years old with stage III colon cancer were being offered SA or CO AC; 2) evaluate the reason for selecting SA vs. CO AC; 3) evaluate the toxicity profile of SA and CO in the elderly; and 4) determine whether a survival benefit exists for elderly pts receiving CO AC. Methods: Pts ≥65 diagnosed with stage III colon cancer at the Cross Cancer Institute from 2004-2010 were identified from the provincial cancer registry. A retrospective analysis of electronic and paper patient records was performed to identify baseline characteristics, AC protocols used, toxicity, dose reductions, dose delays and survival. Results: 258 pts ≥65 years old were diagnosed and treated with AC from 2004-2010. Of these, 168 were treated with SA and 90 with CO AC. The most common reasons for choosing SA AC were patient preference (64%), comorbidities (17%), and lack of drug coverage by provincial formulary (16%). 93 pts ≥age 75 were treated with SA AC, whereas only 20 pts ≥75 were treated with CO AC. Grade 3 and 4 non-hematologic toxicity was more common with CO AC (43% vs. 27%). 20% of all pts had initial dose reductions, with most common reasons being age and comorbidities. 67%, 71% and 29% received dose delays, reductions or drug discontinuation in the SA group, respectively. 72%, 58% and 34% received dose delays, reductions or drug discontinuation in the CO group respectively. 76% of pts received ≥75% of the expected cumulative dose in the SA group, and 81% in the CO group. The 5 year overall survival (OS) of pts who received <75% of expected AC cycles was 63%, compared to 79% in those who received >75% of expected cycles. The 5 year OS was 73% in pts who received SA AC, compared to 84% in those who received CO AC. Conclusions: In elderly pts treated with AC for stage III colon cancer, SA AC is used more frequently than CO AC, based on age, comorbidities, and patient choice. Toxicity with CO AC in elderly pts is high, but may carry a potential a survival benefit for those who receive it.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.005
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.722
Threshold uncertainty score0.558

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.005
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.002
Science and technology studies0.0010.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.101
GPT teacher head0.458
Teacher spread0.357 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2013
Admission routes2
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicCancer Treatment and Pharmacology→French-language works237,207→